Week of September 28, 2026 · 9 stocks
Copper's record high powers the miners while Jazz's cancer-survival data steals biotech's spotlight
Hard assets and the hardware behind AI carried the real conversation this week, from a copper all-time high to a semiconductor-materials index debut, while a gastric-cancer survival win made Jazz Pharmaceuticals the standout.
The feed logged more than 727,000 mentions across a 2,000-plus-name universe this week, and the honest headline is that a striking share of the loudest cashtags weren't stocks at all: memecoins and tokens squatting on symbols like $CAKE, $MOMO, $ETN and $W drove chatter that had nothing to do with Cheesecake Factory, Hello Group, Eaton or Wayfair. Strip those out and a coherent picture emerges: hard assets and the picks-and-shovels of AI. Copper hit an all-time high, a semiconductor-materials supplier crashed the SOX index, a monthly-dividend REIT quietly compounded, and Jazz posted the cleanest cancer-survival readout of the season.
Realty Income drew a spike of chatter, north of 1,000 posts on the week, around a milestone that sounds almost dull until you sit with it: the monthly-dividend REIT declared its 136th dividend increase, roughly 675 consecutive monthly payments.
The crowd ran the compounder pitch with no dissenting voice, framing the quiet raise against a backdrop of Brent near triple digits and rate fears creeping back, and treating the consistency itself as the entire thesis.
The data is defensive rather than dazzling: shares are down about 1% for the year and camped near the bottom of their 52-week range, but Q1 revenue grew 12% to $1.55B at a 47% operating margin, and August's $1B of 3.75% convertible notes gives the acquisition engine cheap fuel. The 5.7% yield is the number posters keep pointing at; the Nov 2 print is where it gets tested.
Few names lit up as sharply relative to their baseline as Jazz Pharmaceuticals, whose 98 posts marked a spike more than 50x its usual hum. The trigger: the Phase 3 HERIZON-GEA-01 trial's second interim readout showed its drug Ziihera plus chemotherapy delivering a statistically significant overall-survival edge in first-line HER2+ gastroesophageal cancer, a median 26.4 months, the longest reported in a Phase 3 for the indication and now published in the NEJM.
The crowd treated it as a clean data win, pointing to ASCO already folding Ziihera into its guidelines and an NCCN Category 1 listing expected within weeks.
The fundamentals back the enthusiasm, with Q2 revenue up 15.5% to $1.21B as the oncology franchise converts, though the honest counter is the insider tape: chairman Bruce Cozadd trimmed $1.5M of stock in early September. Q3 lands Nov 4.
Pure Storage, which our data feed mislabels 'Everpure' thanks to an entity-naming overlap, made the trending cut on hardware momentum rather than a viral moment, and the conversation around it was notably thin.
What sell-side voices there were split into the familiar AI-hardware stalemate: the stock looks 'priced for perfection,' but few want to bet against a name that 'will keep riding the AI hype' as hyperscalers keep buying flash storage.
The numbers explain the patience. Q4 revenue grew 20% to $1.06B at a 70% gross margin, the stock is up 26% year-to-date and 62% over twelve months, and analysts model FY27 revenue near $4.37B. Shares are coiling just under their 200-day average, digesting the run while they wait for the next hyperscale-capex data point.
AIA Group's US ADR is the odd name on the list, surfacing on almost no chatter at all, a $98.6B pan-Asian life insurer that trends on its numbers rather than its noise.
There was no real crowd conversation to speak of; the loudest signal was a Zacks-style 'Strong Sell' tag on Aug 31, a mechanical ranking shift after a strong earnings run rather than a call on the business itself.
And the business looks fine: Q2 revenue rose about 19% to $17.47B with EPS of $1.65 edging past estimates, yet the ADR trades near 20% of its 52-week range and roughly 9% below its 200-day line, record earnings meeting an unloved tape. With no earnings scheduled until March, this is a watch-the-China-new-business-value story more than a this-week one.
Leonardo DRS kept a steady, bullish hum going on the back of a Q2 beat-and-raise that posters kept circling back to: revenue up 10% to $913M, adjusted EPS of $0.35 against a $0.27 estimate, and funded backlog swelling 17% to $5.1B.
The tone leaned into a broader defense-electronics tailwind, with commenters tying DRS's raised outlook to HII's own double beat and reading the whole sub-sector as strong; one dissenter grumbled the company should have paid up to acquire LightPath.
The backlog is being fed in real time: September brought a Korean KDDX destroyer-propulsion award, a $39.6M JTT-X production order, and $96M in MK 41 launch-system electronics. The catch is the insider tape, with two officers selling a combined $1M in early September, and the stock is still down 12% over the year. Q3 prints Oct 29.
Exagen, a $211M autoimmune-diagnostics minnow, rode a diagnostics-sector rotation into the trending list on modest but sustained mentions.
The bull case posters pushed was valuation-driven: the stock trades under 2.5x sales while peers fetch 9-10x, and an expert transcript from a rheumatologist reaffirming the case for its AVISE testing suite gave the thesis a fresh hook, with some looking for the shares to double toward $8-plus. Skeptics were essentially absent.
The financials show a high-margin business still buying growth with cash: Q1 revenue grew nearly 12% to $17.3M at a 59% gross margin, but the company is loss-making, with a -$0.17 quarter and negative free cash flow. Analysts carry a Moderate Buy and model revenue climbing toward breakeven by decade's end. The story is AVISE adoption, and how much the market will pay for it.
Qnity Electronics generated a genuine equity conversation this week, though you had to filter it from a parallel crypto thread squatting on the same $Q symbol. The real catalyst: on Sept 21 the semiconductor-materials supplier was added to the PHLX Semiconductor Index, joining the 30-name SOX cohort that passive funds are obliged to own.
Equity posters ran price-target ladders, entries around $111-122 climbing toward $150 and beyond $195, treating the index inclusion as a fresh mechanical bid layered on top of the story.
The fundamentals are more than a story: Q2 revenue grew 22% to $1.43B at a 19% operating margin, the stock is up 53% year-to-date, and the CEO framed the SOX addition as recognition of the company's role enabling AI and high-performance computing. Shares are coiling into a Nov 17 earnings report that resolves the setup.
Hudbay Minerals spiked hard on the week, mentions running roughly 35x its baseline, as copper punched to a fresh all-time high near $6.89 a pound, with the LME contract setting records around $14,858 a tonne in early September on tariff threats and Chinese grid spending.
The crowd cast Hudbay as one of the year's premier metals plays, citing a +181% twelve-month total return and grouping it with Southern Copper as the North American pure-play cohort to hold through the cycle.
The company fed the narrative itself, disclosing on Sept 28 an extended Snow Lake reserve life out to 18 years alongside an improved production outlook. Q1 revenue had already grown 27% to $757M at a 49% gross margin, and the stock is up 91% over twelve months. The Nov 4 print, and any Peru political-risk commentary, is the next checkpoint.
Unity Software was one of the loudest genuine equities on the feed. A chunk of the $U cashtag belonged to a stablecoin, but the equity read was clearly constructive. The spark: at Meta Connect on Sept 23, Meta unveiled its VR Glasses, and Unity announced day-one engine support the next day, planting its tools at the center of the next VR hardware cycle ahead of a spring 2027 retail launch.
The retail conversation got a boost when investor Chris Camillo publicly entered the name, tagging it a favorite 'GPT-6 trade' on the idea that Unity's Astra AI layer expands model-driven development.
The turnaround is showing in the numbers after a rough 2024-25: Q1 revenue grew 17% to $508M and Q2 delivered a 53% EPS beat. The stock is round-tripping flat for the year, and the CEO's 880,000 price-vesting RSUs set a high bar. Nov 4 earnings decides whether the reacceleration holds.
Full mention counts, sentiment reads and per-name verdicts update live at TickerTalks, including the memecoins we left off this list for wearing equity costumes.
Want this live, not weekly?
See what's trending right now →TickerTalks is a research tool, not financial advice. This recap describes what accounts on X are discussing — it is not a recommendation to buy or sell any security. Social attention is not predictive of future price moves; investing involves risk of loss.
